SALT LAKE CITY, March 21, 2024 (GLOBE NEWSWIRE) — Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that the United States Patent and Trademark Office has issued a patent that will strengthen its ability to deliver a tumor-informed, high-definition, molecular residual disease (MRD) assay to market.  Myriad Genetics Announces Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date

Die moderne Medizin ermöglicht unglaubliches, stellt uns aber gleichzeitig vor neue ethische Herausforderungen. Was ist richtig, was ist falsch, wenn es um Leben und Tod geht? Genau hier setzt das Klinische Ethikkomitee (KEK) am Klinikum Fulda an. Seit 2008 berät es in schwierigen Situationen, in denen medizinische Sachurteile nicht allein ausreichen. Der Vorsitz des KEK […] Klinikum Fulda: Klinische Ethikkomitee mit neuen Vorsitzenden

Thanks to an unusual application of game theory and machine learning technology, a large team of scientists led by experts at Cincinnati Children’s has published the world’s most detailed „atlas“ of the many types of stem cells and early progenitors involved in producing human blood from diverse donors. The team has identified more than 80 distinct subsets of hematopoietic stem and progenitor cells (HSPCs) – early-stage cells that kick off production of mature red cells, white cells and other elements of our complex blood system. Details were published March 21, 2024, in Nature Immunology. „We believe our highly focused capture strategy of the earliest HSPCs, intermediate cell states plus stromal populations, and the most abundant end states provides the deepest view of bone marrow stem and progenitor compartments described to date,“ the co-authors state. The study was led by co-first… 

MONTRÉAL, March 21, 2024 /CNW/ – Novartis Pharmaceuticals Canada Inc. (Novartis Canada) is deeply disappointed with the draft recommendations of the Canadian Drug Expert Committee (CDEC) issued by the Canadian Agency for Drugs and Technologies in Health (CADTH) for LEQVIO® (inclisiran). As an organization, Novartis respects the process conducted by CADTH but at the same time holds a firm belief in the value that LEQVIO brings to patients, clinicians, and the healthcare system. Globally, LEQVIO is widely accessible in 94 countries,4 with public reimbursement in 31 countries,5 and has positively impacted over 178,000 patients.5 https://www.cadth.ca/open-calls-input-and-feedback-0

BNC210 demonstrated a statistically significant improvement in post-traumatic stress disorder (PTSD) symptom severity with a clinically meaningful effect size suggesting a potential advantage over approved medications. Bionomics Reports Results of the Full Dataset Analysis from ATTUNE Phase 2b Trial of BNC210 in Patients with Post-Traumatic Stress Disorder

Gyre Therapeutics Expands Board of Directors with Appointment of Rodney L. Nussbaum Gyre Therapeutics Expands Board of Directors with Appointment of Rodney L. Nussbaum

Strong and secure, LIQUIFIX is the first approved adhesive-based product to affix mesh without penetrating patient tissue Strong and secure, LIQUIFIX is the first approved adhesive-based product to affix mesh without penetrating patient tissue TELA Bio Announces U.S. Commercial Launch of LIQUIFIX™ – the Only FDA-Approved Liquid Adhesive for Internal Use in Hernia Surgery

COPENHAGEN, Denmark, March 21, 2024 – Pursuant to Articles 10-14 of the Articles of Association, the shareholders of Bavarian Nordic A/S are hereby convened to the Annual General Meeting to be held on Bavarian Nordic A/S – Notice Convening Annual General Meeting

NMD Pharma Publishes Comprehensive Data Package for NMD670 in Science Translational Medicine NMD Pharma Publishes Comprehensive Data Package for NMD670 in Science Translational Medicine

SOUTH SAN FRANCISCO, Calif., March 21, 2024 (GLOBE NEWSWIRE) — CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced the appointment of Zhen Su, M.D., M.B.A., an experienced physician executive and leader in the development of oncology therapeutics, to the company’s board of directors. CytomX Therapeutics Appoints Dr. Zhen Su to Board of Directors